429 related articles for article (PubMed ID: 30947585)
41. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
[TBL] [Abstract][Full Text] [Related]
42. Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation.
Sayyed A; Chen C; Gerbitz A; Kim DDH; Kumar R; Lam W; Law AD; Lipton JH; Michelis FV; Novitzky-Basso I; Viswabandya A; Mattsson J; Pasic I
Transplant Cell Ther; 2024 May; 30(5):520.e1-520.e12. PubMed ID: 38462215
[TBL] [Abstract][Full Text] [Related]
43. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Topp MS; Zimmerman Z; Cannell P; Dombret H; Maertens J; Stein A; Franklin J; Tran Q; Cong Z; Schuh AC
Blood; 2018 Jun; 131(26):2906-2914. PubMed ID: 29739753
[TBL] [Abstract][Full Text] [Related]
44. Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.
Hu GH; Zhao XY; Zuo YX; Chang YJ; Suo P; Wu J; Jia YP; Lu AD; Li YC; Wang Y; Jiao SC; Zhang LJ; Kong J; Yan CH; Xu LP; Zhang XH; Liu KY; Cheng YF; Wang Y; Zhang LP; Huang XJ
Leukemia; 2021 Nov; 35(11):3092-3100. PubMed ID: 33824464
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Kobayashi Y; Oh I; Miyamoto T; Lee WS; Iida H; Minami H; Maeda Y; Jang JH; Yoon SS; Yeh SP; Tran Q; Morris J; Franklin J; Kiyoi H
Asia Pac J Clin Oncol; 2022 Jun; 18(3):311-318. PubMed ID: 34185953
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party.
Jung SH; Lee SR; Yang DH; Lee S; Yoon JH; Lee H; Bang SM; Koh Y; Park S; Kim DS; Yhim HY; Kim SH; Lee JH; Sohn SK; Song IC; Lee HG; Cheong JW; Choi Y; Shin HJ
Ann Hematol; 2019 Jan; 98(1):151-158. PubMed ID: 30259121
[TBL] [Abstract][Full Text] [Related]
47. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
48. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Folan SA; Rexwinkle A; Autry J; Bryan JC
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
[TBL] [Abstract][Full Text] [Related]
49. Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data.
Barlev A; Lin VW; Katz A; Hu K; Cong Z; Barber B
Adv Ther; 2017 Jan; 34(1):148-155. PubMed ID: 27873237
[TBL] [Abstract][Full Text] [Related]
50. Insights from the Greek experience of the use of Blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients.
Ampatzidou M; Kattamis A; Baka M; Paterakis G; Anastasiou T; Tzanoudaki M; Kaisari A; Avgerinou G; Doganis D; Papadakis V; Kitra V; Polychronopoulou S
Neoplasma; 2020 Nov; 67(6):1424-1430. PubMed ID: 32701357
[TBL] [Abstract][Full Text] [Related]
51. Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
Stein A; Franklin JL; Chia VM; Arrindell D; Kormany W; Wright J; Parson M; Amouzadeh HR; Choudhry J; Joseph G
Drug Saf; 2019 May; 42(5):587-601. PubMed ID: 30565020
[TBL] [Abstract][Full Text] [Related]
52. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
53. Bispecific antibodies in acute lymphoblastic leukemia therapy.
Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
[TBL] [Abstract][Full Text] [Related]
54. Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia.
Zhou H; Wu X; Yang Z; Lu S; Zhang X; Yang X; Chen S; Wu D; Miao M
Invest New Drugs; 2024 Jun; 42(3):299-308. PubMed ID: 38662275
[TBL] [Abstract][Full Text] [Related]
55. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.
Jen EY; Xu Q; Schetter A; Przepiorka D; Shen YL; Roscoe D; Sridhara R; Deisseroth A; Philip R; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Jan; 25(2):473-477. PubMed ID: 30254079
[TBL] [Abstract][Full Text] [Related]
56. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.
Topp MS; Gökbuget N; Zugmaier G; Degenhard E; Goebeler ME; Klinger M; Neumann SA; Horst HA; Raff T; Viardot A; Stelljes M; Schaich M; Köhne-Volland R; Brüggemann M; Ottmann OG; Burmeister T; Baeuerle PA; Nagorsen D; Schmidt M; Einsele H; Riethmüller G; Kneba M; Hoelzer D; Kufer P; Bargou RC
Blood; 2012 Dec; 120(26):5185-7. PubMed ID: 23024237
[TBL] [Abstract][Full Text] [Related]
57. Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Salhotra A; Yang D; Mokhtari S; Malki MMA; Ali H; Sandhu KS; Aribi A; Khaled S; Mei M; Budde E; Snyder D; Cao T; Spielberger R; Marcucci G; Pullarkat V; Forman SJ; Nakamura R; Stein A; Aldoss I
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1084-1090. PubMed ID: 32035275
[TBL] [Abstract][Full Text] [Related]
58. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Z; Coalter C; Gresham V; Brown T
Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
[TBL] [Abstract][Full Text] [Related]
59. Sequential Therapy of Inotuzumab Ozogamicin and Blinatumomab as a Bridge-to Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Primary Refractory Acute Lymphoblastic Leukemia: A Case Report.
Uchida E; Kurata T; Komori K; Kobayashi J; Kubota N; Sakashita K
J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1228-e1230. PubMed ID: 34001796
[TBL] [Abstract][Full Text] [Related]
60. VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.
Heraudet L; Galtier J; Favre S; Peyraud F; Cazaubiel T; Leroy H; Mottal N; Gros FX; Forcade E; Clément L; Dumas PY; Pigneux A; Leguay T
Br J Haematol; 2022 Aug; 198(3):523-527. PubMed ID: 35524489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]